Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by CROSSJECT

Crossject reports strong manufacturing progress with its epilepsy rescue therapy ZEPIZURE® ahead of filing U.S. Emergency Use Authorization
From CROSSJECT
Via GlobeNewswire
Crossject reports financial results and business highlights for the first six months of 2024
From CROSSJECT
Via GlobeNewswire
Crossject to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024
From CROSSJECT
Via GlobeNewswire
Crossject appoints Tony Tipton as U.S. Chief Operating Officer in Preparation for Commercialization of ZEPIZURE® Epilepsy Rescue Treatment
From CROSSJECT
Via GlobeNewswire
Crossject achieves key ZEPIZURE® manufacturing milestone
From CROSSJECT
Via GlobeNewswire
Crossject to attend H.C. Wainwright 26th Annual Global Investment Conference
From CROSSJECT
Via GlobeNewswire
Crossject is awarded a 6.9 million euros financing from the French Government, as part of the France 2030 innovation plan, to accelerate the development of ZENEO® Epinephrine
From CROSSJECT
Via GlobeNewswire
Crossject elaborates on ZEPIZURE® potential in light of landmark RAMPART study and its own, recently published, bioequivalence study
From CROSSJECT
Via GlobeNewswire
Crossject appoints Dan Chiche, MD as Chief Medical Officer North America
From CROSSJECT
Via GlobeNewswire
Crossject announces highly successful closing of its €8 million rights offering
From CROSSJECT
Via GlobeNewswire
Crossject announces publication of clinical data on ZEPIZURE ® in Neurology and Therapy
From CROSSJECT
Via GlobeNewswire
Crossject signs a geographic extension of ZEPIZURE® commercialization agreement in Europe
From CROSSJECT
Via GlobeNewswire
Crossject reports audited financial results for 2023
From CROSSJECT
Via GlobeNewswire
Crossject advances in its U.S. Strategy and reports Financial Results for 2023
From CROSSJECT
Via GlobeNewswire
Crossject gender equality score reaches 96/100 in 2024
From CROSSJECT
Via GlobeNewswire
Crossject obtains a financing up to €12 million, in two tranches
From CROSSJECT
Via GlobeNewswire
Crossject provides strategic update on priorities for 2024
From CROSSJECT
Via GlobeNewswire
Crossject to host a business briefing on commercial strategy on February 6 at 17:30 CET
From CROSSJECT
Via GlobeNewswire
Crossject to present at Biotech Showcase on January 9 at 16:30 PT
From CROSSJECT
Via GlobeNewswire
Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE®
From CROSSJECT
Via GlobeNewswire
Crossject signs ZEPIZURE® commercialization agreement for northern Europe
From CROSSJECT
Via GlobeNewswire
Crossject announces initiation of coverage by ODDO BHF
From CROSSJECT
Via GlobeNewswire
Crossject reports financial results and business highlights for first half of 2023
From CROSSJECT
Via GlobeNewswire
Crossject announces significant improvement in Gaïa ESG rating
From CROSSJECT
Via GlobeNewswire
Crossject reports successful completion of European and U.S. audits for manufacturing of ZENEO® Midazolam for epileptic seizures
From CROSSJECT
Via GlobeNewswire
Crossject signs new licensing agreement on ZENEO® Midazolam epilepsy rescue therapy with AFT Pharmaceuticals for Australia & New Zealand
From CROSSJECT
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.